Macerated  ||| S:0 E:10 ||| JJ
foot  ||| S:10 E:15 ||| NN
dermatitis  ||| S:15 E:26 ||| VBZ
related  ||| S:26 E:34 ||| VBN
to  ||| S:34 E:37 ||| TO
occlusive  ||| S:37 E:47 ||| VB
footwear  ||| S:47 E:56 ||| JJ
Gram-negative  ||| S:56 E:70 ||| JJ
bacterial  ||| S:70 E:80 ||| JJ
toe-web  ||| S:80 E:88 ||| JJ
infections  ||| S:88 E:99 ||| NNS
( ||| S:99 E:100 ||| -LRB-
GNBTWI ||| S:100 E:106 ||| NNP
's ||| S:106 E:108 ||| POS
)  ||| S:108 E:110 ||| -RRB-
are  ||| S:110 E:114 ||| VBP
relatively  ||| S:114 E:125 ||| RB
under-recognized  ||| S:125 E:142 ||| JJ
among  ||| S:142 E:148 ||| IN
physicians ||| S:148 E:158 ||| NNS
.  ||| S:158 E:160 ||| .
Even  ||| S:160 E:165 ||| RB
though  ||| S:165 E:172 ||| IN
skin  ||| S:172 E:177 ||| NN
infections  ||| S:177 E:188 ||| NNS
are  ||| S:188 E:192 ||| VBP
usually  ||| S:192 E:200 ||| RB
thought  ||| S:200 E:208 ||| VBN
to  ||| S:208 E:211 ||| TO
involve  ||| S:211 E:219 ||| VB
gram-positive  ||| S:219 E:233 ||| JJ
bacteria ||| S:233 E:241 ||| NNS
,  ||| S:241 E:243 ||| ,
gram-negative  ||| S:243 E:257 ||| JJ
organisms  ||| S:257 E:267 ||| NNS
have  ||| S:267 E:272 ||| VBP
a  ||| S:272 E:274 ||| DT
particular  ||| S:274 E:285 ||| JJ
affinity  ||| S:285 E:294 ||| NN
for  ||| S:294 E:298 ||| IN
the  ||| S:298 E:302 ||| DT
toe-web ||| S:302 E:309 ||| JJ
.  ||| S:309 E:311 ||| .
We  ||| S:311 E:314 ||| PRP
present  ||| S:314 E:322 ||| RB
two  ||| S:322 E:326 ||| CD
patients  ||| S:326 E:335 ||| NNS
with  ||| S:335 E:340 ||| IN
GNBTWI ||| S:340 E:346 ||| NNP
's  ||| S:346 E:349 ||| POS
who  ||| S:349 E:353 ||| WP
presented  ||| S:353 E:363 ||| VBD
with  ||| S:363 E:368 ||| IN
maceration  ||| S:368 E:379 ||| NN
of  ||| S:379 E:382 ||| IN
the  ||| S:382 E:386 ||| DT
toe-webs ||| S:386 E:394 ||| JJ
,  ||| S:394 E:396 ||| ,
vesiculopustules  ||| S:396 E:413 ||| NN
and  ||| S:413 E:417 ||| CC
a  ||| S:417 E:419 ||| DT
hyperkeratotic  ||| S:419 E:434 ||| JJ
rim ||| S:434 E:437 ||| NN
.  ||| S:437 E:439 ||| .
Treatment  ||| S:439 E:449 ||| NN
includes  ||| S:449 E:458 ||| VBZ
using  ||| S:458 E:464 ||| VBG
both  ||| S:464 E:469 ||| DT
oral  ||| S:469 E:474 ||| JJ
and  ||| S:474 E:478 ||| CC
topical  ||| S:478 E:486 ||| JJ
antibiotics  ||| S:486 E:498 ||| NN
along  ||| S:498 E:504 ||| IN
with  ||| S:504 E:509 ||| IN
antifungals  ||| S:509 E:521 ||| VBG
to  ||| S:521 E:524 ||| TO
treat  ||| S:524 E:530 ||| VB
co-existing  ||| S:530 E:542 ||| JJ
dermatophyte  ||| S:542 E:555 ||| JJ
infections ||| S:555 E:565 ||| NNS
.  ||| S:565 E:567 ||| .
Awareness  ||| S:567 E:577 ||| NN
of  ||| S:577 E:580 ||| IN
this  ||| S:580 E:585 ||| DT
condition  ||| S:585 E:595 ||| NN
is  ||| S:595 E:598 ||| VBZ
particularly  ||| S:598 E:611 ||| RB
important  ||| S:611 E:621 ||| JJ
for  ||| S:621 E:625 ||| IN
primary  ||| S:625 E:633 ||| JJ
care  ||| S:633 E:638 ||| NN
physicians  ||| S:638 E:649 ||| NNS
in  ||| S:649 E:652 ||| IN
West  ||| S:652 E:657 ||| NNP
Virginia ||| S:657 E:665 ||| NNP
,  ||| S:665 E:667 ||| ,
as  ||| S:667 E:670 ||| IN
a  ||| S:670 E:672 ||| DT
few  ||| S:672 E:676 ||| JJ
of  ||| S:676 E:679 ||| IN
the  ||| S:679 E:683 ||| DT
potential  ||| S:683 E:693 ||| JJ
risk  ||| S:693 E:698 ||| NN
factors  ||| S:698 E:706 ||| NNS
include  ||| S:706 E:714 ||| VBP
wearing  ||| S:714 E:722 ||| VBG
occlusive  ||| S:722 E:732 ||| JJ
footwear ||| S:732 E:740 ||| NN
,  ||| S:740 E:742 ||| ,
such  ||| S:742 E:747 ||| JJ
as  ||| S:747 E:750 ||| IN
work  ||| S:750 E:755 ||| NN
boots ||| S:755 E:760 ||| NNS
,  ||| S:760 E:762 ||| ,
and  ||| S:762 E:766 ||| CC
type  ||| S:766 E:771 ||| NN
II  ||| S:771 E:774 ||| NNP
diabetes  ||| S:774 E:783 ||| NN
mellitus ||| S:783 E:791 ||| NN
.  ||| S:791 E:793 ||| .
